WALTHAM, MASS. – Frenova Renal Research, the world’s only drug and medical device contract clinical development services provider dedicated exclusively to renal research, today announced a collaboration agreement with Pharmaceutical Product Development, LLC (PPD), a leading global contract research organization (CRO). The new relationship expands Frenova’s service offerings while allowing PPD to leverage Frenova’s access to both real-world treatment data and world-leading nephrology experts from the most comprehensive integrated renal care network in the nation.
“Our collaboration with PPD expands the reach of our nephrology experts and broadens the impact of our invaluable treatment data in clinical trials,” said Frenova General Manager Kurt Mussina. “We are pleased to join forces with PPD through our shared commitment of improving the lives of patients living with kidney disease, around the world, through the advancement of renal research.”
As part of Fresenius Medical Care North America (FMCNA)—the continent’s leading provider of kidney care products and services, and a network of more than 2,200 dialysis centers nationwide—Frenova maintains a world-class network of resources encompassing 260 research sites with 450 principal investigators and access to more than 183,000 active ESRD patients and 390,000 active CKD patients. The breadth and depth of Frenova’s data access is rooted in FMCNA’s unmatched ability to gather and analyze immense amounts of patient data from within the company’s own care ecosystem: the company has collected data on more than 1 million patients, including data on more than 250 million dialysis treatments, more than 1 billion medication administrations and over 1 billion laboratory results.
“The opportunity to collaborate with Frenova enhances our ability to connect our clients with researchers recognized as world leaders in the field of nephrology and further strengthens our industry-leading global site and patient capabilities by helping to deliver seamless access to patients, sites and data sources,” said Ulrich Zoeller, Vice President, Project Management, General Medicine for PPD. “Frenova’s access to more than two-thirds of all U.S. nephrology patients, coupled with the breadth of its resources and experience in renal research, will enable PPD to continue to build on its already strong presence in nephrology trials.”
Through the relationship, PPD will offer its clients the therapeutic expertise of Frenova’s global nephrology experts as well as access to F1RST Up™, Frenova’s exclusive alliance of research sites designed to streamline, initiate and enroll clinical studies dramatically faster than industry norms with just-in-time patient recruitment.
Frenova is active in 260 sites across the United States, 15 of which are proprietary Frenova Rapid STart Up (F1RST Up) sites with a strong track record of patient recruitment and retention. The F1RST Up sites use coordinated research processes that enable faster site startup and streamlined study execution.
Frenova is the world’s only drug and medical device contract clinical development services provider dedicated exclusively to renal research. As a Fresenius Medical Care North America company, Frenova manages a networked system of clinical research assets and resources including 260 principal investigators and 450 research sites with clinical trials in kidney disease and its adjacent medical conditions. www.FrenovaRenalResearch.com.
PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 47 countries and more than 18,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development to deliver life-changing therapies that improve health. For more information, visit www.ppdi.com.